Literature DB >> 13116019

Present status of serological tests for cancer.

J J STEIN.   

Abstract

The cancer problem is increasing as life expectancy increases and greater portions of the populace live to the age at which cancer is more likely. Early diagnosis still is difficult. Even with modern methods and with considerable public education with regard to cancer, the disease is often not diagnosed until it is beyond the stage at which cure might be effected. The need for a serodiagnostic test for general screening purposes for cancer detection is tremendous. The major objective of cancer serodiagnostic test methods is to discover a general test that will detect cancer in a high percentage of cases while it is in an early stage; that will give few "false positive" results; that can be done in any laboratory; and that is simple and inexpensive. Many serodiagnostic tests for cancer have been published but none has proven worthy of being a good general test to detect cancer. Yet unless some serodiagnostic test which will be suitable for general screening purposes is developed, it is difficult to see how there can be much improvement in the early diagnosis of cancer, particularly internal cancer. It is hoped that an open-minded attitude will be maintained by physicians on this subject. Recent reports of such a test being developed are encouraging and it is hoped that continued investigations will be confirmatory.

Entities:  

Keywords:  NEOPLASMS/diagnosis

Mesh:

Year:  1954        PMID: 13116019      PMCID: PMC1532696     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  8 in total

1.  Plasma proteins in cancer.

Authors:  R J WINZLER
Journal:  Adv Cancer Res       Date:  1953       Impact factor: 6.242

2.  Studies of various tests for malignant neoplastic diseases. VI. Tests for the least coagulable serum protein and the iodoacetate index.

Authors:  L D ELLERBROOK; E C MEEK; S W LIPPINCOTT
Journal:  J Natl Cancer Inst       Date:  1951-08       Impact factor: 13.506

3.  Studies of various tests for malignant neoplastic diseases. VII. Serum inhibitors of chymotrypsin and trypsin.

Authors:  A C PEACOCK; J J SHEEHY
Journal:  J Natl Cancer Inst       Date:  1952-02       Impact factor: 13.506

4.  Effect of cancer on liver enzymes.

Authors:  J P GREENSTEIN
Journal:  J Am Med Assoc       Date:  1952-03-01

5.  Studies of various tests for malignant neoplastic diseases. I. The reduction of methylene blue by plasma.

Authors:  N ERIKSEN; L D ELLERBROOK; S W LIPPINCOTT
Journal:  J Natl Cancer Inst       Date:  1951-02       Impact factor: 13.506

6.  Studies of various tests for malignant neoplastic diseases. V. The heat "coagulation" of plasma.

Authors:  N ERIKSEN; L D ELLERBROOK; E C MEEK; S W LIPPINCOTT
Journal:  J Natl Cancer Inst       Date:  1951-02       Impact factor: 13.506

7.  Tumor lipoids. II. Clinical evaluation of a serologically active nonsaponifiable fraction of liver of cancer-bearing patients.

Authors:  G C HALL; A H DOWDY; H S PENN; A W BELLAMY
Journal:  J Natl Cancer Inst       Date:  1952-06       Impact factor: 13.506

8.  Tumor lipoids. I. Preparation of a serologically active nonsaponifiable fraction of liver of cancer bearing patients.

Authors:  H S PENN
Journal:  J Natl Cancer Inst       Date:  1952-06       Impact factor: 13.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.